Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

small cell carcinoma - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

small cell carcinoma

MONDO:0000402

Also known as:oat cell canceroat cell carcinomasmall cell NEC

Find Clinical TrialsTrials

Overview

A neuroendocrine carcinoma composed of small malignant cells which are often said to resemble "oat cells" under the microscope. Small cell carcinoma most often affects the lungs. Clinically, this is often a rapidly growing cancer that spreads to distant sites early.

Clinical Trials296 registered · 40 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

No HPO annotations are available for this condition.

GeneReviews

Clinical Guidance

Retinoblastoma. The most common presenting sign is a white pupillary reflex (leukocoria). Strabismus is the second most common presenting sign and may accompany or precede leukocoria . Unusual presenting signs include glaucoma, orbital cellulitis, uveitis, hyphema, or vitreous hemorrhage. Most affected children are diagnosed before age five years. Atypical manifestations are more frequent in older children. Probands with retinoblastoma usually present in one of the following clinical settings:

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

Guidelines for diagnosis and care of children and families affected by retinoblastoma have been published .

Suggestive Findings

Retinoblastoma should be suspected in children with any of the following:

Leukocoria (white pupil)
Strabismus
Change in eye appearance

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for small cell carcinoma. The disease remains an area of unmet medical need.

Gene therapy approaches for small cell carcinoma have been reported in the published literature.

GeneReviews

Management Guidelines

Guidelines for retinoblastoma care have been developed (see and Kenya National Retinoblastoma Strategy Best Practice Guidelines).

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with retinoblastoma, the following evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended:

Prognosis

Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.

GeneReviews

Surveillance Guidelines

Guidelines for clinical screening for children at risk have been published . Further information regarding medical surveillance for those who have had or are at risk of developing retinoblastoma is available in the guidelines for retinoblastoma care. Children who have undergone successful treatment require frequent follow-up examination for early detection of newly arising intraocular tumors, as indicated in the guidelines.

Table 3.

Retinoblastoma: Recommended Surveillance for Individuals at Risk and Affected Individuals

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

296 clinical trials registered, 40 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 2 PHASE4, 28 PHASE3, 106 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07454642](https://clinicaltrials.gov/study/NCT07454642)

Data assembled from 4 of 12 sources · Last updated Nov 3, 2026, 3:00 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are any of the 296 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	157	37%
Laboratory research	66	15%
Research summaries	57	13%
Disease patterns and progression	50	12%
Testing and diagnosis research	45	11%
Clinical study results	32	7%
New treatment approaches	11	3%
Other research	9	2%

Kisho

small cell carcinoma

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Evaluations Following Initial Diagnosis

Prognosis

Surveillance Guidelines

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Heritable retinoblastoma

Establishing the Diagnosis

Differential Diagnosis

Clinical Trials

Persons w/RB1 germline pathogenic variant (H1)

Persons w/unilateral retinoblastoma w/o germline RB1 pathogenic variant (H0*)2

Persons w/retinoma(s)

Non-ocular tumors

Recent Publications

Latest News & Developments

Bladder preservation is still feasible in the rare aggressive small cell carcinoma subtype.

small cell carcinoma

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Evaluations Following Initial Diagnosis

Prognosis

Surveillance Guidelines

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Heritable retinoblastoma

Establishing the Diagnosis

Differential Diagnosis

Clinical Trials

Persons w/RB1 germline pathogenic variant (H1)

Persons w/unilateral retinoblastoma w/o germline RB1 pathogenic variant (H0*)2

Persons w/retinoma(s)

Non-ocular tumors

Recent Publications

Latest News & Developments

Bladder preservation is still feasible in the rare aggressive small cell carcinoma subtype.